Arbós P, Wirth M, Arangoa M A, Gabor F, Irache J M
Centro Galénico, Universidad de Navarra, Apartado 177, C/Irunlarrea s/n, Pamplona, Spain.
J Control Release. 2002 Oct 30;83(3):321-30. doi: 10.1016/s0168-3659(02)00015-9.
The aim of this study was to evaluate the feasibility and in vitro activity of ligand-conjugates based on the use of poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA or Gantrez AN). Fluorescently labelled PVM/MA nanoparticles were prepared by desolvation and cross-linkage with 1,3-diaminopropane (DP). Conjugates were obtained by incubation between the carriers and Sambucus nigra agglutinin (SNA) for 1 h in an aqueous medium. The lectin binding to the surface of nanoparticles was increased by both increasing the bulk ligand concentration and decreasing the amount of cross-linker. However, a concentration of about 0.3-0.4 mg DP per mg polymer was necessary to obtain maximum agglutination activity. Under optimal conditions, the amount of fixed ligand was 46 microg/mg nanoparticle (binding efficiency of 86%); although the activity of SNA conjugates was 13.3 microg/mg particle. The activity of nanoparticles, measured by the association to Caco-2 monolayers, was higher when SNA was covalently bound onto their surface. The lectin-conjugate interaction was 6-fold higher than conventional nanoparticles. Moreover, energy-dependent mechanisms were only observed in SNA-PVM/MA particles. Finally, the decrease in association in the presence of lactose demonstrates that both SNA- and SNA-conjugate-binding was due to a true lectin-sugar interaction.
本研究的目的是评估基于聚(甲基乙烯基醚 - 顺丁烯二酸酐)(PVM/MA或Gantrez AN)的配体 - 共轭物的可行性和体外活性。通过去溶剂化并用1,3 - 二氨基丙烷(DP)交联制备荧光标记的PVM/MA纳米颗粒。通过在水性介质中将载体与黑接骨木凝集素(SNA)孵育1小时获得共轭物。通过增加大量配体浓度和减少交联剂用量,凝集素与纳米颗粒表面的结合增加。然而,每毫克聚合物需要约0.3 - 0.4毫克DP的浓度才能获得最大凝集活性。在最佳条件下,固定配体的量为46微克/毫克纳米颗粒(结合效率为86%);尽管SNA共轭物的活性为13.3微克/毫克颗粒。当SNA共价结合到其表面时,通过与Caco - 2单层的结合测量的纳米颗粒的活性更高。凝集素 - 共轭物相互作用比传统纳米颗粒高6倍。此外,仅在SNA - PVM/MA颗粒中观察到能量依赖性机制。最后,在乳糖存在下结合的减少表明SNA和SNA - 共轭物结合均归因于真正的凝集素 - 糖相互作用。
J Control Release. 2002-10-30
Int J Pharm. 2002-8-21
J Control Release. 2003-4-14
Artif Cells Blood Substit Immobil Biotechnol. 2012-12
Eur J Pharm Biopharm. 2009-10-9
Arch Insect Biochem Physiol. 2011-1-19
Pharmaceutics. 2023-3-23